GlassScriptPhysician profile
Allen E Tate
NPI 1144479098
$1,849.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.35 · 2022: $21.51 · 2023: $1,619 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $406.52 | 2023-2024 | Roxybond |
| Collegium Pharmaceutical, INC. | $262.84 | 2023-2024 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.05 | 2021-2023 | Relistor |
| Abbvie INC. | $198.18 | 2023-2024 | |
| Lundbeck LLC | $172.31 | 2023-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $86.97 | 2023 | Ztlido |
| Ibsa Pharma INC. | $79.84 | 2022-2023 | Tirosint, Licart |
| Nevro Corp. | $62.35 | 2023-2024 | Senza |
| Amgen INC. | $57.22 | 2023 | Evenity, Prolia |
| Pfizer INC. | $57.11 | 2023 | |
| Tersera Therapeutics LLC | $44.75 | 2023 | Prialt |
| Azurity Pharmaceuticals, INC. | $41.61 | 2023 | Horizant |
| Novo Nordisk INC | $32.23 | 2023 | Rybelsus |
| Abbott Laboratories | $24.13 | 2023 | Eterna |
| Kowa Pharmaceuticals America, INC. | $21.18 | 2023 | Seglentis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $21.09 | 2023 | Dysport |
| Mdd US Operations, LLC | $19.30 | 2021 | |
| Lilly USA, LLC | $14.91 | 2021 | |
| Medtronic, INC. | $14.57 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.